Skip Navigation

Comparative Effectiveness of Therapies for Reducing the Risk of Primary Breast Cancer: Guidance for Shared Decision Making


This educational program for clinicians provides information about the Agency for Healthcare Research and Quality's (AHRQ's) systematic review of the comparative effectiveness and safety of tamoxifen, raloxifene, and tibolone for reducing the risk of primary breast cancer in women. It guides clinicians in discussing AHRQ's findings with women who may be candidates for FDA-approved therapies.

At the conclusion of this activity, the participant should be able to:
  • Compare the effectiveness of tamoxifen, raloxifene, and tibolone in the general population and specific subpopulations of at-risk women
  • Evaluate key differences in side effects, harms, persistence, and adherence associated with tamoxifen, raloxifene, and tibolone
  • Apply the findings in clinical settings to help at-risk women make informed and shared decisions about whether to use risk-reducing medications


PRIME Education, Inc.

Funding Sources

Agency for Healthcare Research and Quality

QualityTool Topic



  • Release Date: 07/2011
  • Original Summary: 10/2011
Disclaimer: The inclusion of a tool in the Innovations Exchange does not constitute or imply an endorsement by the U.S. Department of Health and Human Services, the Agency for Healthcare Research and Quality or Westat of the tool or of the submitter or developer of the tool. Read more.

Last updated: April 11, 2012.